Voya Large Cap Value Fund Quarterly Commentary - 3Q25
Actively managed large cap value strategy that relies on fundamental research to capture the benefits of high excess capital yield and sustainable dividends.
Portfolio review
U.S. equities posted significant gains for the quarter. The S&P 500 increased by 8.12%, while the Nasdaq Composite rose by 11.24%. Strong performance in technology and artificial intelligence-related stocks, along with a shift toward easing monetary policy drove the market higher. The technology and communication services sectors outperformed while consumer staples sector lagged. Small cap stocks beat large cap stocks, and growth outperformed value stocks.
During the quarter, U.S. corporate earnings significantly exceeded expectations and 3Q25 forecasts indicate continued strength. Meanwhile, the full impact from tariffs had not yet filtered through earnings, and trade negotiations were ongoing. In addition, the U.S. Federal Reserve cut rates in September following weaker labor data. The combination of strong earnings, ongoing trade talks, and the onset of a likely Fed easing cycle bolstered overall market sentiment during the quarter.
For the quarter ended September 30, 2025, the Fund underperformed the Index on a NAV basis due to unfavorable stock selection. Stock selection within the consumer staples, financials, and health care sectors detracted the most from performance. Conversely, the communication services, real estate, and consumer discretionary sectors contributed to performance.
At the individual stock level our overweight positions in Kenvue, Inc. (KVUE), Centene Corp. (CNC), and Globant SA (GLOB) detracted from performance the most.
An overweight position in Kenvue, Inc. (KVUE) detracted from performance following the controversy around Tylenol and its alleged health risks.
An overweight position in Centene Corp. (CNC) detracted from performance as CNC reported weaker-than-expected 2Q25 results. Earnings per share (EPS) came below expectations, driven by elevated Medical Loss Ratios (MLR) in both Medicaid and Affordable Care Act (ACA) segments. Additionally, the stock declined sharply after Centene withdrew its 2025 guidance, citing lower-than-anticipated enrollment in its Health Insurance Marketplace.
An overweight position in Globant SA (GLOB) detracted from performance. While the company reported in-line 2Q25 results, it reduced its full-year outlook and 3Q25 guidance due to the downstream impact of Department of Government Efficiency (DOGE) on a large U.S. client.
An overweight position in Warner Bros. Discovery, Inc. (WBD), owning a non-benchmark in AbbVie, Inc. (ABBV), and our position in combined shares of Alphabet Inc. (GOOGL) were the biggest individual contributors.
Our overweight position in Warner Bros. Discovery, Inc. (WBD) contributed to performance. Shares surged on speculation that Paramount Skydance (PSKY) may pursue a full acquisition of WBD ahead of its planned corporate split.
Owning a non-benchmark in AbbVie, Inc. (ABBV) contributed to performance. Shares rose following a strong earnings report, with growth in EPS and revenue supported by strength across its oncology, immunology, and neuroscience drug portfolios.
Our position in the combined shares of Alphabet Inc. (GOOGL) contributed to performance this quarter, driven by strong 2Q25 results. Revenue growth was broad-based, with notable strength across Search, YouTube, and Cloud. Additionally, the announcement that Alphabet will not be required to sell Chrome, coupled with a regulatory shift acknowledging increased competition from artificial intelligence (AI), further supported the stock’s performance.
Current strategy and outlook
The U.S. economy navigates a complex landscape of interest rate changes, inflation concerns, and labor market dynamics. Due to the emerging signs of labor market softness, the Fed is expected to cut rates further. Solid economic data, strong corporate earnings, and easing monetary policy are boosting the attractiveness of U.S. assets, despite existing concerns.
Holdings detail
Companies mentioned in this report—percentage of Strategy investments, as of 09/30/25: Kenvue, Inc. 1.85%, Centene Corp. 0.85%, Globant SA 0.36%, Warner Bros. Discovery, Inc. 0.64%, AbbVie, Inc. 1.60% and Alphabet Inc. 3.71%, 0% indicates that the security is no longer in the portfolio. Portfolio holdings are subject to daily change.
Key Takeaways
Equity markets rebounded in the third quarter of 2025, recovering from April’s tariff-driven volatility and ending well above mid-year levels. Growth outperformed value, led by strong gains in technology and communication services, while consumer staples lagged, remaining the sole sector detractor, driven by early-quarter weakness. Easing inflation, selective rate cuts, and increased demand for safe-haven assets shaped cross-asset dynamics. Higher beta and deep value also participated meaningfully in the rally.
For the quarter ended September 30, 2025, the Fund underperformed the Russell 1000 Value Index the (Index) on a net asset value (NAV) basis due to unfavorable stock selection. Stock selection within the consumer staples, financials, and health care sectors detracted the most from performance. Conversely, the communication services, real estate, and consumer discretionary sectors contributed to performance.
As we enter the final stretch of the year, investors face persistent geopolitical tensions, policy uncertainty, and inflation risks. Market leadership is expanding beyond mega-cap stocks, creating opportunities in defensive and cyclical sectors. We aim to remain nimble amid ongoing macroeconomic and market uncertainty.